Want to see CBIO full AI Analyst Report?
Total Valuation
Crescent Biopharma has a market cap or net worth of $625.50M. The enterprise value is $383.42.
Market Cap$625.50M
Enterprise Value$383.42
Share Statistics
Crescent Biopharma has 37,143,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding37,143,940
Owned by Insiders11.26%
Owned by Institutions2.02%
Financial Efficiency
Crescent Biopharma’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.58%.
Return on Equity (ROE)-0.76
Return on Assets (ROA)-0.64
Return on Invested Capital (ROIC)-74.58%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee246.45K
Profits Per Employee-3.50M
Employee Count44
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Crescent Biopharma is ―. Crescent Biopharma’s PEG ratio is 0.02.
PE Ratio―
PS Ratio11.39
PB Ratio0.61
Price to Fair Value0.61
Price to FCF-0.86
Price to Operating Cash Flow-7.07
PEG Ratio0.02
Income Statement
In the last 12 months, Crescent Biopharma had revenue of 10.84M and earned -153.94M in profits. Earnings per share was -14.78.
Revenue10.84M
Gross Profit10.84M
Operating Income-152.63M
Pretax Income-151.94M
Net Income-153.94M
EBITDA-149.67M
Earnings Per Share (EPS)-14.78
Cash Flow
In the last 12 months, operating cash flow was -72.68M and capital expenditures -80.94M, giving a free cash flow of -153.62M billion.
Operating Cash Flow-72.68M
Free Cash Flow-153.62M
Free Cash Flow per Share-4.14
Dividends & Yields
Crescent Biopharma pays an annual dividend of $0.24, resulting in a dividend yield of ―
Dividend Per Share$0.24
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change30.54%
50-Day Moving Average17.06
200-Day Moving Average14.98
Relative Strength Index (RSI)53.22
Average Volume (3m)145.41K
Important Dates
Crescent Biopharma upcoming earnings date is Nov 5, 2026, After Close (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Crescent Biopharma as a current ratio of 6.56, with Debt / Equity ratio of 0.88%
Current Ratio6.56
Quick Ratio6.56
Debt to Market Cap0.00
Net Debt to EBITDA1.41
Interest Coverage Ratio-69.85
Taxes
In the past 12 months, Crescent Biopharma has paid 2.00M in taxes.
Income Tax2.00M
Effective Tax Rate-0.01
Enterprise Valuation
Crescent Biopharma EV to EBITDA ratio is 0.59, with an EV/FCF ratio of 0.61.
EV to Sales-8.12
EV to EBITDA0.59
EV to Free Cash Flow0.61
EV to Operating Cash Flow1.23
Balance Sheet
Crescent Biopharma has $171.59M in cash and marketable securities with $1.44M in debt, giving a net cash position of $170.16M billion.
Cash & Marketable Securities$171.59M
Total Debt$1.44M
Net Cash$170.16M
Net Cash Per Share$4.58
Tangible Book Value Per Share$19.49
Margins
Gross margin is 100.00%, with operating margin of -1407.52%, and net profit margin of -1419.61%.
Gross Margin100.00%
Operating Margin-1407.52%
Pretax Margin-1401.16%
Net Profit Margin-1419.61%
EBITDA Margin-1380.24%
EBIT Margin-1381.01%
Analyst Forecast
The average price target for Crescent Biopharma is $29.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$29.50
Price Target Upside80.98% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast78.59%